Found 150 matching trials
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC NA Hepatocellular carcinoma (HCC) is a leading global cause of cancer-related ...
Show More Location
Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Learn More & Join Trial
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection PHASE3 To compare the impact on recurrence risk of adjuvant Sintilimab (a recombin...
Show More Location
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Learn More & Join Trial
Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer PHASE2 Consistent with previous literature, the investigators postulate that a leu...
Show More Location
Qilu Hospital of Shandong University
Learn More & Join Trial
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer PHASE2 This is a single-arm, phase II study aiming to evaluate the feasibility and...
Show More Location
Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital
Learn More & Join Trial
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer N/A Managements for refractory proficient mismatch repair (pMMR) or microsatell...
Show More Location
Hunan Cancer hospital
Learn More & Join Trial
Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma PHASE2 Ovarian clear cell carcinoma (OCCC) is one of the rare subtypes of ovarian ...
Show More Location
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Learn More & Join Trial
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma N/A Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and programme...
Show More Location
Chinese PLA General hospital
Learn More & Join Trial
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC PHASE1 Chemotherapeutic agents exert significant immunomodulatory effects by influ...
Show More Location
the First Affiliated Hospital of Zhengzhou University
Learn More & Join Trial
Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer PHASE2 This study is a single-center, randomized controlled, phase II clinical tri...
Show More Location
Multiple Locations
Learn More & Join Trial
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial PHASE3 This is a randomized, controlled clinical trial based on prior exploratory ...
Show More Location
Guangdong Provincial People's Hospital
Learn More & Join Trial